Srinivas R. Valluri

Pfizer, Inc.

235 East 42 Street

New York, NY 10017

United States

SCHOLARLY PAPERS

6

DOWNLOADS
Rank 10,258

SSRN RANKINGS

Top 10,258

in Total Papers Downloads

8,794

SSRN CITATIONS
Rank 30,822

SSRN RANKINGS

Top 30,822

in Total Papers Citations

37

CROSSREF CITATIONS

0

Scholarly Papers (6)

1.

Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study

Number of pages: 40 Posted: 23 Aug 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Southern California Kaiser Permanente Medical Group, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente - Southern California Kaiser Permanente Medical Group, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 5,583 (2,897)

Abstract:

Loading...

2.

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 18 Jan 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 2,112 (14,337)

Abstract:

Loading...

omicron, effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, kaiser

3.

BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 30 Jun 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 386 (146,807)
Citation 1

Abstract:

Loading...

BA.2, BA.1, omicron, effectiveness, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, Kaiser Permanente, real-world

4.

Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study

Number of pages: 35 Posted: 21 Dec 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 384 (147,645)
Citation 5

Abstract:

Loading...

effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, cohort, delta

5.

Effectiveness of the BNT162b2 XBB.1.5-Adapted Vaccine Against COVID-19 Hospitalization Related to the JN.1 Variant in Europe: A Test-Negative Case-Control Study Using the id.Drive Platform

Number of pages: 37 Posted: 11 Jun 2024
Pfizer, Inc., P95 Pharmacovigilance and Epidemiology Services, Pfizer, Inc., P95 Pharmacovigilance and Epidemiology Services, P95 Pharmacovigilance and Epidemiology Services, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Autonomous University of Barcelona - Hospital Universitari Vall d'Hebron, University Hospital Ulm, P95 Pharmacovigilance and Epidemiology Services, P95 Pharmacovigilance and Epidemiology Services, University Hospital Ulm, University of Genova - Department of Health Sciences, Ziekenhuis Netwerk Antwerpen (ZNA), Centre Hospitalier Universitaire St-Pierre, FISABIO-Public Health, Universitat Autònoma de Barcelona (UAB), Instituto de Salud Carlos III, Goethe University Frankfurt, Freiburg University, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc. and P95 Pharmacovigilance and Epidemiology Services
Downloads 220 (262,322)

Abstract:

Loading...

COVID-19, SARS-CoV-2, COVID-19 vaccination, vaccine effectiveness, BNT162b2, XBB adapted vaccine, JN.1

6.

Incidence of Community Acquired Lower Respiratory Tract Disease in Bristol, UK During the COVID-19 Pandemic

Number of pages: 31 Posted: 19 Apr 2022
University of Bristol - Population Health Sciences, University of Bristol - Department of Mathematics, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, University Hospitals Bristol NHS Foundation Trust - Clinical Research and Imaging Centre, University of Bristol - Academic Respiratory Unit, University of Bristol - Department of Population Health Sciences, University of Bristol - Population Health Sciences, University of Bristol - Department of Population Health Sciences, Pfizer, Inc., Pfizer, Inc., University of Bristol - Bristol Vaccine Centre, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., University of Bristol - Department of Population Health Sciences, University of Bristol - Academic Respiratory Unit, Pfizer Inc. - Medical and Scientific Affairs, University of Bristol - Engineering Mathematics and University of Bristol - Bristol Vaccine Centre
Downloads 109 (470,202)
Citation 5

Abstract:

Loading...

pneumonia, lower respiratory tract infection, cardiac failure, COVID-19, SARS-CoV-2